Among the subset of patients with a baseline serum uric level below 10 mg/dL, as is the case for a large majority of gout patients seen in clinical practice, the response rate to the highest dose of RDEA594 was 58%. The side effect profile of RDEA594 was comparable to placebo, added Dr. Perez-Ruiz of Hospital de Cruces in Vizcaya, Spain.
Ardea Biosciences, San Diego, which is developing RDEA594, has not decided whether to take the drug into phase III trials as monotherapy or in combination with febuxostat, with which RDEA594 has shown synergistic effects, a company official said in an interview with
Disclosures: Dr. Schlesinger has received research grants from Brownwood Acres and Novartis. Dr. Kitt is employed by Nuon Therapeutics Inc. Dr. Perez-Ruiz is a consultant to Ardea Biosciences.
As a result of its anti-inflammatory effect, cherry juice concentrate halves levels of interleukin-1-beta and TNF-alpha.
Source DR. SCHLESINGER